Murex Releases New Version of MX.3 for Investment Management
Murex, the leading provider of capital markets solutions, announces a new release of MX.3 for Investment Management, a fully integrated solution for cross-asset portfolio management. The solution is tailored to the requirements of asset managers while leveraging the power and functionality of Murex's market leading front-to-back-to-risk platform.
In the current economic and regulatory environment, asset managers are having to diversify their investments to meet clients' needs and to improve performance. Both regulators and investors are demanding greater transparency, with fuller reporting and explanation of results. Securities and cash inventories need to be consolidated in a timely manner and managed more proactively to meet the evolving margining requirements for cleared and non-cleared products.
Randa Saghieh, head of Murex Asset Management, comments: “More sophisticated risk analytics are required, not only to comply with new rules, but also to enable managers to include risk more effectively in their investment decisions. Our new solution has evolved to support clients in all these challenges.”
Among the extended features of the new release is an enhanced version of
the Investment Management Risk & Performance Attribution module. The
module takes advantage of the extensive cross-asset coverage and
sophisticated pricing and risk analytics capabilities of the MX.3
platform with detailed decomposition of risk and performance by effects,
at any aggregate or detailed level.
This makes it easier for managers to monitor their sources of risk ex-ante, and how their bets are placed, as well as to explain the risk/return decisions ex-post to investors. Managers can now also rebalance their portfolio against an optimal portfolio so that it aligns with their ex ante risk expectations.
The release also benefits from major investments in the Collateral space: managers can now rely on full collateral management and transformation capacity including securities and cash, margining, and margin call processing.
MX.3 for Investment Management provides full automation throughout the investment lifecycle, integrating performance attribution and other dedicated portfolio management functionality with order management, compliance and risk. Asset managers can rely on MX.3 strong instruments offering to diversify their investments to meet clients' return expectations and improve performance.
With the new release of MX.3 for Investment Management, Murex is demonstrating its commitment to the buy side and continuing to grow its market share.
Since its creation in 1986, Murex has played a key role in proposing
effective technology as a catalyst for growth and innovation in capital
markets, through the design and implementation of integrated trading,
portfolio management, risk management, processing and post-trade
Driven by innovation, Murex’s MX.3 Front-to-Back-to-Risk platform leverages the firm’s collective experience and expertise, accumulated through its strategic client partnerships, to offer an unrivalled asset class coverage and best-of-breed business solutions at every step of the financial trade lifecycle.
Clients worldwide benefit from the MX.3 platform’s modular set of business solutions, specifically designed to solve the multi-faceted challenges of a transforming financial industry, while relying on the strength of 2,000 dedicated specialists.
To learn more, please visit https://www.murex.com/ or follow us on Twitter @Murex_Group .
Mireille Adebiyi, +33 1 44 05 32 00.
Murex Global Marketing Communications Manager,
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
NJ-CELGENE17.2.2018 22:02 | pressemeddelelse
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers
CELLTRION-HEALTHCARE17.2.2018 09:02 | pressemeddelelse
CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study
AVANTI-COMMUNICATIONS16.2.2018 19:28 | pressemeddelelse
Avanti Communications HYLAS 4 Satellite Arrives in French Guiana
KY-GENERAL-CABLE-CORP16.2.2018 18:07 | pressemeddelelse
General Cable Corporation Stockholders Approve Acquisition By Prysmian Group
BOEHRINGER-INGELHEIM16.2.2018 10:05 | pressemeddelelse
Systemic Sclerosis World Congress: Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease
PHILIP-MORRIS-INTL16.2.2018 09:02 | pressemeddelelse
Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum